Lateral ventricles

Regeneration Biomedical Doses First Patient in a First-in-Human Phase I Clinical Trial of Stem Cell Therapy delivered directly into the brain of Patients with Alzheimer’s Disease

Retrieved on: 
Tuesday, April 23, 2024
FDA, Brain, Inflammation, Cell, Safety, Hope, Research, Collection, IRB, B cell, Lateral ventricles, Stem cell, Patent, Patient, Regeneration, Caregiver, BBB, Scalp, Multiple sclerosis, Adipose tissue, Neuron, Traumatic brain injury, Biomarker, Clinical trial, RBI, Pharmaceutical industry

Stem cells have represented a novel approach to treatment, but evidence of efficacy has been elusive because systemically administered cells are unable to bypass the blood brain barrier (BBB) and enter the brain.

Key Points: 
  • Stem cells have represented a novel approach to treatment, but evidence of efficacy has been elusive because systemically administered cells are unable to bypass the blood brain barrier (BBB) and enter the brain.
  • Our RB-ADSC product candidate is designed to overcome the BBB by delivering potentially efficacious stem cells directly to the brain.
  • In vivo studies demonstrated that stem cells injected in this fashion do locate into the ventricles and parenchyma.
  • Research in two animal models has demonstrated that stem cells infused into the ventricular system distribute themselves into brain parenchyma.

Viz.ai Receives FDA 510(k) Clearance for Artificial Intelligence Algorithm for the Quantification of Intracerebral Hemorrhage

Retrieved on: 
Thursday, February 8, 2024
Technology, Hospitals, FDA, Health Technology, Cardiology, Software, Practice Management, Health, Data Management, Artificial Intelligence, Radiology, Viz, Neurology, Brain, FRCSC, NCCT, Food, Food and Drug Administration, ICH, AI, University, UTHealth School of Dentistry, MPH, Multimedia, Neurosurgery, Hospital, Stroke, Lateral ventricles, Disease, Intracerebral hemorrhage

“This technology, which marries precision with AI, is poised to transform how we approach intracerebral hemorrhage cases."

Key Points: 
  • “This technology, which marries precision with AI, is poised to transform how we approach intracerebral hemorrhage cases."
  • Intracerebral hemorrhage accounts for up to 15% of all strokes and has high morbidity and mortality rates, demanding swift response.
  • Accurate volume measurements of brain bleeds are crucial for assessing the severity of cases, monitoring progression, and planning treatment strategies.
  • Viz ICH Plus exemplifies our dedication to enhancing patient care by leveraging technology," stated Jayme Strauss, chief clinical officer at Viz.ai.

Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Positive Biomarker/Clinical Correlations from Phase 2 Biomarker Study at AAIC in Amsterdam

Retrieved on: 
Tuesday, July 11, 2023
Research, Other Health, General Health, Pharmaceutical, Biometrics, Mental Health, Clinical Trials, Science, Neurology, Biotechnology, FDA, Health, Other Science, Genotype, Atrophy, MH, Cerebral amyloid angiopathy, CAA, Prevalence, Pathology, NDA, Black box, COVID, Siderosis, Biomarker, MCI, Doctor of Philosophy, Female, Mild, Common, Blood, Plasma, MRI, Alzheimer's disease, ARIA, Occipital bone, Magnetic resonance imaging, Cortex, MD, Patient, Risk, Horseshoe kidney, CEST, Lateral ventricles, Composite, Medicine, Drug development, Oral, AD, Cerebral edema, MMSE, Conference, Neurotoxicity, Safety, Disease, Pharmaceutical industry, Medical imaging, APOE4, Alzheon, Early

ALZ-801 (valiltramiprosate) is an investigational oral disease-modifying therapy in Phase 3 development for the treatment of Early AD.

Key Points: 
  • ALZ-801 (valiltramiprosate) is an investigational oral disease-modifying therapy in Phase 3 development for the treatment of Early AD.
  • In mechanism-of-action studies, ALZ-801 fully blocked the formation of neurotoxic soluble beta amyloid (Aβ) oligomers at the Phase 3 clinical dose.
  • This population is the focus of Alzheon’s pivotal Phase 3 APOLLOE4 trial , which is now fully enrolled and will be completed in the third quarter of 2024.
  • We look forward to communicating the final 24-month data from our Phase 2 study later in 2023.”